PIM1

Last updated
PIM1
Protein PIM1 PDB 1xqz.png
Available structures
PDB Ortholog search: PDBe RCSB
Identifiers
Aliases PIM1 , PIM, Pim-1 proto-oncogene, serine/threonine kinase
External IDs OMIM: 164960 MGI: 97584 HomoloGene: 11214 GeneCards: PIM1
Orthologs
SpeciesHumanMouse
Entrez

5292

18712

Ensembl

ENSG00000137193

ENSMUSG00000024014

UniProt

P11309

P06803

RefSeq (mRNA)

NM_002648
NM_001243186

NM_008842
NM_001364913

RefSeq (protein)

NP_001230115
NP_002639

NP_032868
NP_001351842

Location (UCSC) Chr 6: 37.17 – 37.18 Mb Chr 17: 29.71 – 29.72 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Proto-oncogene serine/threonine-protein kinase Pim-1 is an enzyme that in humans is encoded by the PIM1 gene. [5] [6] [7]

Pim-1 is a proto-oncogene which encodes for the serine/threonine kinase of the same name. The pim-1 oncogene was first described in relation to murine T-cell lymphomas, as it was the locus most frequently activated by the Moloney murine leukemia virus. [8] Subsequently, the oncogene has been implicated in multiple human cancers, including prostate cancer, acute myeloid leukemia and other hematopoietic malignancies. [9] Primarily expressed in spleen, thymus, bone marrow, prostate, oral epithelial, hippocampus and fetal liver cells, Pim-1 has also been found to be highly expressed in cell cultures isolated from human tumors. [8] Pim-1 is mainly involved in cell cycle progression, apoptosis and transcriptional activation, as well as more general signal transduction pathways. [8] Pim-1's role in oncogenic signalling has led to it becoming a widely studied target in cancer research, with numerous drug candidates under investigation which target it. [10] [11]

Gene

Located on chromosome 6 (6p21.2), the gene encompasses 5Kb of DNA, including 6 exons and 5 introns. Expression of Pim-1 has been shown to be regulated by the JAK/STAT pathway. Direct binding of transcription factors STAT3 and STAT5 to the Pim-1 promoter results in the transcription of Pim-1. [8] The Pim-1 gene has been found to be conserved in dogs, cows, mice, rats, zebrafish and C. elegans . Pim-1 deficient mice have been shown to be phenotypically normal, indicating that there is redundancy in the function of this kinase. [8] In fact, sequence homology searches have shown that two other Pim-1-like kinases, Pim-2 and Pim-3, are structurally and functionally similar. [8] The Pim-1 gene encodes has multiple translation initiation sites, resulting in two proteins of 34 and 44kD. [8]

Protein structure

Human, murine and rat Pim-1 contain 313 amino acids, and have a 94 – 97% amino acid identity. [8] The active site of the protein, ranging from amino acids 38-290, is composed of several conserved motifs, including a glycine loop motif, a phosphate binding site and a proton acceptor site. [8] Modification of the protein at amino acid 67 (lysine to methionine) results in the inactivation of the kinase. [8]

Activation and stabilization

Pim-1 is primarily involved in cytokine signaling, and has been implicated in many signal transduction pathways. Because Pim-1 transcription is initiated by STAT3 and STAT5, its production is regulated by the cytokines that regulate the STAT pathway, or STAT factors. These include interleukins (IL-2, IL-3,IL-5, IL-6, IL-7, IL12, IL-15), prolactin, TNFα, EGF and IFNγ, among others. [8] Pim-1 itself can bind to negative regulators of the JAK/STAT pathway, resulting in a negative feedback loop.

Although little is known about the post-transcriptional modifications of Pim-1, it has been hypothesized that Hsp90 is responsible for the folding and stabilization of Pim-1, although the exact mechanism has yet to be discovered. [8] Furthermore, the serine/threonine phosphatase PP2 has been shown to degrade Pim-1.

Interactions

PIM1 has been shown to interact with:

Other known substrates/binding partners of Pim-1 include proteins involved in transcription regulation (nuclear adaptor protein p100, HP-1, PAP-1 and TRAF2 / SNX6), and regulation of the JAK/STAT pathway (SOCS1 and SOCS3). [8] Furthermore, Pim-1 has been shown to be a cofactor for c-Myc, a transcription factor believed to regulate 15% of all genes, and their synergy has been in prostate tumorigenesis. [20]

Pim-1 is able to phosphorylate many targets, including itself. Many of its targets are involved in cell cycle regulation.

Activates

Deactivates

Clinical implications

Pim-1 is directly involved in the regulation of cell cycle progression and apoptosis, and has been implicated in numerous cancers including prostate cancer, Burkitt's lymphoma and oral cancer, as well as numerous hematopoietic lymphomas. Single nucleotide polymorphisms in the Pim-1 gene have been associated with increased risk for lung cancer in Korean patients, and have also been found in diffuse large cell lymphomas. [21] As well as showing useful activity against a range of cancers, [11] PIM kinase inhibitors have also been suggested as possible treatments for Alzheimer's disease. [22] PIM expression is sufficient to drive resistance to anti-angiogenic agents in prostate and colon cancer models, although the mechanism is not fully elucidated. [23] It has been suggested that a co-targeted therapeutic approach to inhibition of Pim-1 in cancer may be preferable, with suggested co-targets including the PI3K pathway and more. [10] PIM1 expression was found to be elevated during aging and to contribute to the development of pulmonary fibrosis. [24]

Inhibitors

A large number of small molecule inhibitors of PIM1 have been developed. Clinical trial results so far have showed promising anti-cancer activity, but side effects due to insufficient selectivity have proved problematic and research continues to find more potent and selective inhibitors for this target. [25] [26] [27] [28] [29] [30] [31] [10] [11]

Examples

Related Research Articles

<span class="mw-page-title-main">Philadelphia chromosome</span> Genetic abnormality in leukemia cancer cells

The Philadelphia chromosome or Philadelphia translocation (Ph) is a specific genetic abnormality in chromosome 22 of leukemia cancer cells. This chromosome is defective and unusually short because of reciprocal translocation, t(9;22)(q34;q11), of genetic material between chromosome 9 and chromosome 22, and contains a fusion gene called BCR-ABL1. This gene is the ABL1 gene of chromosome 9 juxtaposed onto the breakpoint cluster region BCR gene of chromosome 22, coding for a hybrid protein: a tyrosine kinase signaling protein that is "always on", causing the cell to divide uncontrollably by interrupting the stability of the genome and impairing various signaling pathways governing the cell cycle.

<span class="mw-page-title-main">GSK-3</span> Class of enzymes

Glycogen synthase kinase 3 (GSK-3) is a serine/threonine protein kinase that mediates the addition of phosphate molecules onto serine and threonine amino acid residues. First discovered in 1980 as a regulatory kinase for its namesake, glycogen synthase (GS), GSK-3 has since been identified as a protein kinase for over 100 different proteins in a variety of different pathways. In mammals, including humans, GSK-3 exists in two isozymes encoded by two homologous genes GSK-3α (GSK3A) and GSK-3β (GSK3B). GSK-3 has been the subject of much research since it has been implicated in a number of diseases, including type 2 diabetes, Alzheimer's disease, inflammation, cancer, addiction and bipolar disorder.

<span class="mw-page-title-main">Protein kinase B</span> Set of three serine threonine-specific protein kinases

Protein kinase B (PKB), also known as Akt, is the collective name of a set of three serine/threonine-specific protein kinases that play key roles in multiple cellular processes such as glucose metabolism, apoptosis, cell proliferation, transcription, and cell migration.

<span class="mw-page-title-main">Phosphoinositide 3-kinase</span> Class of enzymes

Phosphoinositide 3-kinases (PI3Ks), also called phosphatidylinositol 3-kinases, are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer.

<span class="mw-page-title-main">ACVR1C</span> Protein-coding gene in the species Homo sapiens

The activin A receptor also known as ACVR1C or ALK-7 is a protein that in humans is encoded by the ACVR1C gene. ACVR1C is a type I receptor for the TGFB family of signaling molecules.

<span class="mw-page-title-main">Acute myeloblastic leukemia with maturation</span> Medical condition

Acute myeloblastic leukemia with maturation (M2) is a subtype of acute myeloid leukemia (AML).

<span class="mw-page-title-main">CHEK2</span> Protein-coding gene in humans

CHEK2 is a tumor suppressor gene that encodes the protein CHK2, a serine-threonine kinase. CHK2 is involved in DNA repair, cell cycle arrest or apoptosis in response to DNA damage. Mutations to the CHEK2 gene have been linked to a wide range of cancers.

<span class="mw-page-title-main">PAK1</span> Mammalian protein found in Homo sapiens

Serine/threonine-protein kinase PAK 1 is an enzyme that in humans is encoded by the PAK1 gene.

<span class="mw-page-title-main">CHEK1</span> Protein-coding gene in humans

Checkpoint kinase 1, commonly referred to as Chk1, is a serine/threonine-specific protein kinase that, in humans, is encoded by the CHEK1 gene. Chk1 coordinates the DNA damage response (DDR) and cell cycle checkpoint response. Activation of Chk1 results in the initiation of cell cycle checkpoints, cell cycle arrest, DNA repair and cell death to prevent damaged cells from progressing through the cell cycle.

<span class="mw-page-title-main">BRAF (gene)</span> Protein-coding gene in the species Homo sapiens

BRAF is a human gene that encodes a protein called B-Raf. The gene is also referred to as proto-oncogene B-Raf and v-Raf murine sarcoma viral oncogene homolog B, while the protein is more formally known as serine/threonine-protein kinase B-Raf.

<span class="mw-page-title-main">PLK1</span> Mammalian protein found in Homo sapiens

Serine/threonine-protein kinase PLK1, also known as polo-like kinase 1 (PLK-1) or serine/threonine-protein kinase 13 (STPK13), is an enzyme that in humans is encoded by the PLK1 gene.

<span class="mw-page-title-main">CDC25A</span> Protein-coding gene in the species Homo sapiens

M-phase inducer phosphatase 1 also known as dual specificity phosphatase Cdc25A is a protein that in humans is encoded by the cell division cycle 25 homolog A (CDC25A) gene.

<span class="mw-page-title-main">STAT5A</span> Protein-coding gene in the species Homo sapiens

Signal transducer and activator of transcription 5A is a protein that in humans is encoded by the STAT5A gene. STAT5A orthologs have been identified in several placentals for which complete genome data are available.

<span class="mw-page-title-main">Proto-oncogene tyrosine-protein kinase Src</span> Mammalian protein found in humans

Proto-oncogene tyrosine-protein kinase Src, also known as proto-oncogene c-Src, or simply c-Src, is a non-receptor tyrosine kinase protein that in humans is encoded by the SRC gene. It belongs to a family of Src family kinases and is similar to the v-Src gene of Rous sarcoma virus. It includes an SH2 domain, an SH3 domain and a tyrosine kinase domain. Two transcript variants encoding the same protein have been found for this gene.

<span class="mw-page-title-main">STK3</span> Protein-coding gene in the species Homo sapiens

Serine/threonine-protein kinase 3 is an enzyme that in humans is encoded by the STK3 gene.

<span class="mw-page-title-main">PLK2</span> Protein-coding gene in the species Homo sapiens

Serine/threonine-protein kinase PLK2 is an enzyme that in humans is encoded by the PLK2 gene.

<span class="mw-page-title-main">PIM2 (gene)</span> Protein-coding gene in the species Homo sapiens

Serine/threonine-protein kinase Pim-2 is an enzyme that in humans is encoded by the PIM2.

<span class="mw-page-title-main">KIAA1524</span> Protein-coding gene in the species Homo sapiens

Protein CIP2A also known as cancerous inhibitor of PP2A (CIP2A) is a protein that in humans is encoded by the KIAA1524 gene.

<span class="mw-page-title-main">Hippo signaling pathway</span> Signaling pathway that controls organ size

The Hippo signaling pathway, also known as the Salvador-Warts-Hippo (SWH) pathway, is a signaling pathway that controls organ size in animals through the regulation of cell proliferation and apoptosis. The pathway takes its name from one of its key signaling components—the protein kinase Hippo (Hpo). Mutations in this gene lead to tissue overgrowth, or a "hippopotamus"-like phenotype.

<span class="mw-page-title-main">PI3K/AKT/mTOR pathway</span> Cell cycle regulation pathway

The PI3K/AKT/mTOR pathway is an intracellular signaling pathway important in regulating the cell cycle. Therefore, it is directly related to cellular quiescence, proliferation, cancer, and longevity. PI3K activation phosphorylates and activates AKT, localizing it in the plasma membrane. AKT can have a number of downstream effects such as activating CREB, inhibiting p27, localizing FOXO in the cytoplasm, activating PtdIns-3ps, and activating mTOR which can affect transcription of p70 or 4EBP1. There are many known factors that enhance the PI3K/AKT pathway including EGF, shh, IGF-1, insulin, and CaM. Both leptin and insulin recruit PI3K signalling for metabolic regulation. The pathway is antagonized by various factors including PTEN, GSK3B, and HB9.

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000137193 - Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000024014 - Ensembl, May 2017
  3. ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ↑ "Entrez Gene: PIM1 pim-1 oncogene".
  6. ↑ Domen J, Von Lindern M, Hermans A, et al. (June 1987). "Comparison of the human and mouse PIM-1 cDNAs: nucleotide sequence and immunological identification of the in vitro synthesized PIM-1 protein". Oncogene Research. 1 (1): 103–12. PMID   3329709.
  7. ↑ Meeker TC, Nagarajan L, ar-Rushdi A, et al. (June 1987). "Characterization of the human PIM-1 gene: a putative proto-oncogene coding for a tissue specific member of the protein kinase family". Oncogene Research. 1 (1): 87–101. PMID   3329711.
  8. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Bachmann M, Möröy T (April 2005). "The serine/threonine kinase Pim-1". The International Journal of Biochemistry & Cell Biology. 37 (4): 726–30. doi:10.1016/j.biocel.2004.11.005. PMID   15694833.
  9. ↑ "Pim-1 Oncogene" . Retrieved 2015-12-14.
  10. 1 2 3 Luszczak S, Kumar C, Sathyadevan VK, et al. (2020). "PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer". Signal Transduction and Targeted Therapy. 5: 7. doi:10.1038/s41392-020-0109-y. PMC   6992635 . PMID   32025342.
  11. 1 2 3 Malone T, Schäfer L, Simon N, et al. (March 2020). "Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer" (PDF). Pharmacology & Therapeutics. 207: 107454. doi:10.1016/j.pharmthera.2019.107454. PMID   31836451. S2CID   209357486.
  12. ↑ Koike N, Maita H, Taira T, et al. (February 2000). "Identification of heterochromatin protein 1 (HP1) as a phosphorylation target by Pim-1 kinase and the effect of phosphorylation on the transcriptional repression function of HP1(1)". FEBS Letters. 467 (1): 17–21. doi: 10.1016/S0014-5793(00)01105-4 . PMID   10664448. S2CID   29392124.
  13. ↑ Mochizuki T, Kitanaka C, Noguchi K, et al. (June 1999). "Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway". The Journal of Biological Chemistry. 274 (26): 18659–66. doi: 10.1074/jbc.274.26.18659 . PMID   10373478.
  14. ↑ Mizuno K, Shirogane T, Shinohara A, et al. (March 2001). "Regulation of Pim-1 by Hsp90". Biochemical and Biophysical Research Communications. 281 (3): 663–9. doi:10.1006/bbrc.2001.4405. PMID   11237709.
  15. ↑ Rainio EM, Sandholm J, Koskinen PJ (February 2002). "Cutting edge: Transcriptional activity of NFATc1 is enhanced by the Pim-1 kinase". Journal of Immunology. 168 (4): 1524–7. doi: 10.4049/jimmunol.168.4.1524 . PMID   11823475.
  16. ↑ Bhattacharya N, Wang Z, Davitt C, et al. (July 2002). "Pim-1 associates with protein complexes necessary for mitosis". Chromosoma. 111 (2): 80–95. doi:10.1007/s00412-002-0192-6. PMID   12111331. S2CID   26016943.
  17. ↑ Wang Z, Bhattacharya N, Mixter PF, et al. (December 2002). "Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1593 (1): 45–55. doi: 10.1016/S0167-4889(02)00347-6 . PMID   12431783.
  18. ↑ Leverson JD, Koskinen PJ, Orrico FC, et al. (October 1998). "Pim-1 kinase and p100 cooperate to enhance c-Myb activity". Molecular Cell. 2 (4): 417–25. doi: 10.1016/S1097-2765(00)80141-0 . PMID   9809063.
  19. ↑ Nihira K, Ando Y, Yamaguchi T, et al. (April 2010). "Pim-1 controls NF-kappaB signalling by stabilizing RelA/p65". Cell Death and Differentiation. 17 (4): 689–98. doi: 10.1038/cdd.2009.174 . PMID   19911008.
  20. ↑ Wang J, Kim J, Roh M, et al. (April 2010). "Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma". Oncogene. 29 (17): 2477–87. doi:10.1038/onc.2010.10. PMC   2861731 . PMID   20140016.
  21. ↑ Kim DS, Sung JS, Shin ES, et al. (December 2008). "Association of single nucleotide polymorphisms in PIM-1 gene with the risk of Korean lung cancer". Cancer Research and Treatment. 40 (4): 190–6. doi:10.4143/crt.2008.40.4.190. PMC   2697471 . PMID   19688129.
  22. ↑ Velazquez R, Shaw DM, Caccamo A, et al. (July 2016). "Pim1 inhibition as a novel therapeutic strategy for Alzheimer's disease". Molecular Neurodegeneration. 11 (1): 52. doi: 10.1186/s13024-016-0118-z . PMC   4944476 . PMID   27412291.
  23. ↑ Casillas AL, Toth RK, Sainz AG, et al. (2018). "Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents". Clinical Cancer Research. 24 (1): 169–180. doi:10.1158/1078-0432.CCR-17-1318. PMC   6214353 . PMID   29084916.
  24. ↑ Pham TX, Lee J, Guan J, et al. (February 2022). "Transcriptional analysis of lung fibroblasts identifies PIM1 signaling as a driver of aging-associated persistent fibrosis". JCI Insight. 7 (6). doi:10.1172/jci.insight.153672. PMC   8986080 . PMID   35167499.
  25. ↑ Morwick T (February 2010). "Pim kinase inhibitors: a survey of the patent literature". Expert Opinion on Therapeutic Patents. 20 (2): 193–212. doi:10.1517/13543770903496442. PMID   20100002. S2CID   19401237.
  26. ↑ Merkel AL, Meggers E, Ocker M (April 2012). "PIM1 kinase as a target for cancer therapy". Expert Opinion on Investigational Drugs. 21 (4): 425–36. doi:10.1517/13543784.2012.668527. PMID   22385334. S2CID   26602099.
  27. ↑ Foulks JM, Carpenter KJ, Luo B, et al. (May 2014). "A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas". Neoplasia. 16 (5): 403–412. doi:10.1016/j.neo.2014.05.004. PMC   4198696 . PMID   24953177.
  28. ↑ Arunesh GM, Shanthi E, Krishna MH, et al. (January 2014). "Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update". Expert Opinion on Therapeutic Patents. 24 (1): 5–17. doi:10.1517/13543776.2014.848196. PMID   24131033. S2CID   2331769.
  29. ↑ Keane NA, Reidy M, Natoni A, et al. (July 2015). "Targeting the Pim kinases in multiple myeloma". Blood Cancer Journal. 5 (7): e325. doi:10.1038/bcj.2015.46. PMC   4526774 . PMID   26186558.
  30. ↑ Le BT, Kumarasiri M, Adams JR, et al. (2015). "Targeting Pim kinases for cancer treatment: opportunities and challenges". Future Medicinal Chemistry . 7 (1): 35–53. doi:10.4155/fmc.14.145. PMID   25582332.
  31. ↑ Tursynbay Y, Zhang J, Li Z, et al. (February 2016). "Pim-1 kinase as cancer drug target: An update". Biomedical Reports. 4 (2): 140–146. doi:10.3892/br.2015.561. PMC   4734217 . PMID   26893828.
  32. ↑ Keeton EK, McEachern K, Dillman KS, et al. (February 2014). "AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia". Blood. 123 (6): 905–13. doi: 10.1182/blood-2013-04-495366 . PMC   3916880 . PMID   24363397.
  33. ↑ Burger MT, Nishiguchi G, Han W, et al. (November 2015). "Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies". Journal of Medicinal Chemistry. 58 (21): 8373–86. doi:10.1021/acs.jmedchem.5b01275. PMID   26505898.
  34. ↑ Mumenthaler SM, Ng PY, Hodge A, et al. (October 2009). "Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes". Molecular Cancer Therapeutics. 8 (10): 2882–93. doi: 10.1158/1535-7163.MCT-09-0293 . PMC   2808126 . PMID   19825806.
  35. ↑ Chen LS, Redkar S, Taverna P, et al. (July 2011). "Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia". Blood. 118 (3): 693–702. doi: 10.1182/blood-2010-12-323022 . PMC   3142906 . PMID   21628411.
  36. ↑ Foulks JM, Carpenter KJ, Luo B, et al. (May 2014). "A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas". Neoplasia. 16 (5): 403–12. doi: 10.1016/j.neo.2014.05.004 . PMC   4198696 . PMID   24953177.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.